Hawkins Richard J 4

What Happened
Richard J. Hawkins, a director of PLUS Therapeutics, acquired 922 shares on July 1, 2026 through the exercise/conversion of a derivative reported on Form 4 (transaction code M). The filing shows a $0.00 exercise price, meaning no cash was paid to convert the restricted stock units (RSUs) into common shares. The Form 4 also lists a corresponding "disposed" derivative entry, which reflects the conversion of the RSU instrument into the underlying shares rather than a sale.

Key Details

• Transaction date: 2026-07-01
• Transaction type/code: Exercise/conversion of a derivative (M); paired derivative disposition entry for the same 922 shares
• Price: $0.00 per share (no cash paid)
• Shares acquired: 922 common shares (via RSU conversion)
• Shares owned after transaction: Not disclosed in the filing
• Footnotes: F1—each RSU represents a contingent right to one share; F2—vesting occurs in four substantially equal quarterly installments beginning July 1, 2026 (this 922-share conversion appears to be one installment)
• Filing timeliness: No late filing noted

Context
This was an RSU vesting/conversion, not an open-market purchase or a sale. Converting RSUs to shares at $0 is a routine compensation event and does not by itself indicate a buy or sell signal. The filing does not show any immediate sale of these shares or tax-withholding dispositions.